Rises and falls in donor-specific and third-party HLA antibody levels after antibody incompatible transplantation

Transplantation

Volumn 87, Issue 6, 2009, Pages 882-888

  Higgins, Rob ^a,d   Lowe, David ^b   Hathaway, Mark ^b   Lam, For ^a   Kashi, Habib ^a   Tan, Lam Chin ^a   Imray, Chris ^a   Fletcher, Simon ^a   Chen, Klaus ^a   Krishnan, Nithya ^a   Hamer, Rizwan ^a,c   Zehnder, Daniel ^a,c   Briggs, David ^b  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^b NHS BLOOD AND TRANSPLANT   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

^d UNIVERSITY HOSPITAL COVENTRY   (United Kingdom)

Author keywords

Antibody incompatible transplantation; HLA antibodies; Plasmapheresis

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; DONOR SPECIFIC HLA ANTIBODY; HLA ANTIBODY; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; UNCLASSIFIED DRUG; ALLOANTIBODY; DRUG DERIVATIVE; HLA ANTIGEN; HLA DR ANTIGEN; MYCOPHENOLIC ACID;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; ORGAN DONOR; ORGAN TRANSPLANTATION; PLASMAPHERESIS; PRIORITY JOURNAL; REPEATED DRUG DOSE; SENSITIZATION; SINGLE DRUG DOSE; TREATMENT OUTCOME; BLOOD GROUP INCOMPATIBILITY; CLINICAL TRIAL; GRAFT REJECTION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; LIVING DONOR; METHODOLOGY; MULTICENTER STUDY; STATISTICS;

BLOOD GROUP INCOMPATIBILITY; FEMALE; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HLA-DR ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MYCOPHENOLIC ACID; PREDNISOLONE; TACROLIMUS;

EID: 65549101698     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31819a6788     Document Type: Article

References (19)

1. Morris PJ, Monaco AP. Antibody revisited. Transplantation 2004; 78: 179.
2. Matinlauri IH, Kyllönen LE, Eklund BH, et al. Weak humoral posttransplant alloresponse after a well-HLA-matched cadaveric kidney transplantation. Transplantation 2004; 78: 198.
3. Mao Q, Terasaki PI, Cai J, et al. Extremely high association between appearance ofHLAantibodies ands failure of kidney grafts in a five year longitudinal study. Am J Transplant 2007; 7: 864.
4. Worthington JE, Martin S, Al-Husseini DM, et al. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003; 75: 1034.
5. Palmer A, Bewick M, Kennedy L, et al. Anti-HLA antibodies following the transplantation of highly sensitised renal allograft recipients. Transplant Proc 1989; 21: 766.
6. Bevan DJ, Carey BS, Fallon M, et al. Modulation of anti-HLA antibody production following renal transplantation in sensitised, immunoadsorbed patients. Transplant Proc 1997; 29: 1448.
7. Halloran PF, Wadgymar A, Ritchie S, et al. The significance of the anti-Class 1 antibody response. I. Clinical and pathologic features of anti-Class I-mediated rejection. Transplantation 1990; 49: 85.
8. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into crossmatch positive recipients. Transplantation 2000; 70: 887.
9. Gloor JM, DeGoey S, Ploeger N, et al. Persistence of low levels of alloantibody after desensitisation in crossmatch-positive living-donor kidney transplantation. Transplantation 2004; 78: 221.
10. Pollinger HS, Stegall MD, Gloor JM, et al. Kidney transplantation in patients with antibodies against donor HLA class II. Am J Transplant 2007; 7: 857.
11. Zachary AA, Montgomery RA, Ratner LE, et al. Specific and durable elimination of antibody to donor HLA antigens in renal transplant recipients. Transplantation 2003; 76: 1519.
12. Zachary AA, Montgomery RA, Leffell MS. Factors associated with predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin. Human Immunol 2005; 66: 364.
13. Anglicheau D, Loupy A, Suberielle C, et al. Posttranspant prophylactic intravenous immunoglobulin in kidney transplant patients at high immunological risk: A pilot study. Am J Transplant 2007; 7: 1185.
14. Higgins R, Hathaway M, Lowe D, et al. Blood levels of donor-specific HLA antibodies after renal transplantation; resolution of rejection in the presence of circulating donor specific antibody. Transplantation 2007; 84: 876.
15. Williams GM, Hume DM, Hudson RP Jr, et al. "Hyperacute" renalhomograft rejection in man. N Engl J Med 1968; 279: 611.
16. Heinemann FM, Roth I, Rebmann V, et al. Immunoglobulin isotypespecific characterization of anti-human leukocyte antigen antibodies eluted from explanted renal allografts. Hum Immunol 2007; 68: 500.
17. Stunz LL, Karr RW, Anderson RA. HLA-DRB1 and -DRB4 genes are differentially regulated at the transcriptional level. J Immunol 1989; 143: 3081.
18. Fuggle SV, McWhinnie DL, Morris PJ. Precise specificity of induced tubular HLA-class II antigens in renal allografts. Transplantation 1987; 44: 214.
19. Reed E, Hardy M, Benvenist A, et al. Effect of antiidiotypic antibodies to HLA on graft survival in renal-allograft recipients. N Engl J Med 1987; 316: 1450.